— Amarin Corporation plc (NASDAQ: AMRN) reported earnings of $0.04 per share in the fourth-quarter 2019 vs. $0.02 per share loss expected.
— Revenue grew 85% to $143.3 million, versus $136.01 million expected. Net product revenue increased 84% year-over-year to $142 million, driven mainly by an increase in total Vascepa prescriptions in the US.
— For full-year 2020, Amarin expects revenues to be $650 million to $700 million.
— AMRN shares gained 2% during the aftermarket hours.
Most Popular
DIS Earnings: All you need to know about Walt Disney’s Q4 2025 earnings results
The Walt Disney Company (NYSE: DIS) reported its fourth quarter 2025 earnings results today. Revenues of $22.5 billion were comparable to the year-ago quarter. Net income attributable to The Walt
Cisco (CSCO) reports higher Q1 revenue and earnings; results beat estimates
Network gear maker Cisco Systems Inc. (NASDAQ: CSCO) on Wednesday announced financial results for the first quarter of fiscal 2026, reporting higher revenue and profit. Earnings, on an adjusted basis,
Advantage of CERo’s CER receptor lies in native human protein-based antigen binding: CEO
CERo Therapeutics Holdings, Inc. is a biotechnology company pioneering engineered T cell immunotherapies to combat cancer, with a focus on hematologic malignancies and solid tumors. In an email conversation with
